DBV Technologies S.A. (NASDAQ:DBVT) Receives $38.25 Average Target Price from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have received an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $38.25.

A number of analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. Citizens Jmp increased their price objective on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday, December 17th. Guggenheim restated a “buy” rating and issued a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research report on Wednesday, December 17th.

DBV Technologies Stock Performance

Shares of DBVT opened at $21.87 on Wednesday. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -4.23 and a beta of -0.97. The stock has a fifty day moving average price of $20.93 and a two-hundred day moving average price of $16.08. DBV Technologies has a 52-week low of $3.91 and a 52-week high of $26.18.

Insider Buying and Selling at DBV Technologies

In related news, major shareholder Bpifrance Epic sold 1,292,103 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57. Following the completion of the transaction, the insider owned 7,303,369 shares in the company, valued at $30,601,116.11. The trade was a 15.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 3,369,627 shares of company stock valued at $15,489,908 over the last three months. Company insiders own 1.44% of the company’s stock.

Institutional Investors Weigh In On DBV Technologies

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vivo Capital LLC bought a new position in DBV Technologies during the second quarter worth about $9,659,000. Artisan Partners Limited Partnership bought a new stake in shares of DBV Technologies in the 3rd quarter valued at about $519,000. Nan Fung Trinity HK Ltd. acquired a new stake in shares of DBV Technologies in the 2nd quarter valued at approximately $340,000. New York State Common Retirement Fund acquired a new stake in shares of DBV Technologies in the 3rd quarter valued at approximately $34,000. Finally, Cetera Investment Advisers bought a new position in DBV Technologies during the 4th quarter worth approximately $251,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.